• Webinar Library

IMS Health Webinar Library

Q2 2016 IMS Health Conference Call and Webcast

27.07.2016

Listen to the webcast of the Q2 2016 IMS Health earnings conference call.

PrEP, Pipelines and Payer Pressure: The Next Decade of HIV Treatment

30.06.2016

Experts from IMS Health’s Disease Insights team review the clinical and commercial strategies life sciences companies are adopting to address the changing HIV treatment landscape. The webinar also highlights the drug development pipeline and market forecasts for HIV drugs in key geographies.

Using Insights from Anonymous Patient-Level Data for Incentive Compensation

22.06.2016

In this webinar replay, IMS Health experts focus on how anonymous patient-level data in specialty markets can drive change. We also feature a side-by-side analysis of key markets to answer questions around the use of traditional sales data results compared to using anonymous patient-level data.

Market Opportunities from the Aging Population: Focus on Alzheimer’s Disease and Parkinson’s Disease

01.06.2016

In this IMS Disease Insights webinar about aging, experts from the IMS Disease Insights team will discuss the market potential arising from the global aging population, focusing on current clinical and commercial market dynamics and opportunities for two key segments of the pharmaceutical market: Alzheimer's disease and Parkinson's disease. The discussion will include a review of the drug development pipeline and market forecasts for these two therapy areas.

Q1 2016 IMS Health Earnings Conference Call

03.05.2016

Listen to the webcast of the Q1 2016 IMS Health earnings conference call.

Immuno-oncology: Defining a New Era in Cancer Care

27.04.2016

In this IMS Disease Insights oncology webinar replay, experts from the IMS Disease Insights and IMS Thought Leadership teams discuss the exciting immuno-oncology market, focusing on current clinical and commercial market dynamics and opportunities. Register to download the recording.

The Essential European Revolution: Why Multichannel is Vital to Europe

05.04.2016

This hour-long session focuses on the future of multichannel marketing in Europe—and why life sciences companies can and should embrace this approach to drive their commercial operations and engage an increasingly diverse set of stakeholders. 

Delivering on the Potential of Biosimilar Medicines

29.03.2016

The purpose of this report is to describe the potential role for biosimilars and their contribution to healthcare systems; the risks for stakeholders to realize that full potential value; and the requirements for competitive functioning markets in order to capture the full value. It draws on analysis of trends across EU nations over the past decade and observations of the differing practices undertaken by stakeholder groups.

Can novel biologics and fixed-dose combinations offset the patent cliff in a crowded respiratory market?

24.03.2016

In this IMS Health Disease Insights webinar, IMS Health autoimmune experts will discuss the asthma and COPD markets, focusing on current clinical and commercial market dynamics and opportunities. The speakers will then review the drug development pipeline, identifying the likely winners, and present a summary of the 10-year market outlook for asthma and COPD.

IMS Institute Global Medicines Use in 2020

09.12.2015

Director of Research Michael Kleinrock discusses key findings from the IMS Institute for Healthcare Informatics report Global Medicines Use in 2020: Outlook and Implications.  According to the report, the volume of medicines used globally will reach 4.5 trillion doses and cost $1.4 trillion by 2020—a 30 percent rise in spending from 2015 levels. Within five years, more than half of the world’s population will live in countries where medicine use will exceed one dose per person each day as the medicine use gap between developed and pharmerging markets narrows.

The Three Myths Of Multi-Channel Marketing

27.10.2015

Multichannel marketing is still far from mature. Almost all companies need to move from sporadic, disconnected initiatives to a coherent strategy. This move entails fundamental changes in commercial functions, from organisational structure and budgeting priorities to cultural change, altering deeply engrained assumptions about commercial activity, impact and measurement.

IMS Health's 2015 Incentive Compensation Benchmarking Survey Results

20.10.2015

Incentive compensation experts Dan Ganse and Ann Kane from IMS Health discuss gaining a better understanding of how your peer organizations are incentivizing their field organizations and key takeaways from our 2015 Incentive Compensation Benchmarking Study.  

Gaining Insight into your Medicaid Liability

16.07.2015

IMS Health expert Lynn Lewis, Director, Data Acquisition and Integrity, Compliance, Data Niche Unit, IMS Health, shares examples of potential retrospective analyses you can perform to help you justify or adjust your Medicaid accrual.

Medicine Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014

16.07.2015

Michael Kleinrock, Director, Research Development, IMS Institute for Healthcare Informatics, reviews the key findings from the IMS Health Institute for Healthcare Informatics report, Medicine Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014.

Q1 2015 IMS Health Conference Call and Webcast

29.04.2015

Listen to the webcast of the Q1 2015 IMS Health earnings conference call.

Buggy Whips and Driverless Cars - How Pharma Needs to Engage with IDN

28.04.2015

View a PharmaForce-IMS Health Webinar with IMS Health’s Senior Principals, John Daly and Elizabeth Powers. They will discuss how IDN needs and priorities intersect with those of pharma and how they can work together to achieve optimal value through the product.

Can an early stage pipeline offset the loss of exclusivity for key ulcerative colitis and Crohn’s disease brands in the IBD market?

22.04.2015

IMS Health’s Pam Narang, PhD., autoimmune analyst, Disease Insights, shares information about the inflammatory bowel disease (IBD) market focusing on current clinical and commercial market dynamics and opportunities.

Staring into the Abyss? Navigating the NHS post election

15.04.2015

IMS Health and pharmaphorum experts discuss the implications of the U.K.’s upcoming national election on the country’s health system – specifically market access for specialist treatments in the post-election environment. Panelists include IMS Health’s Angela McFarlane, senior principal, Local Market Access; Dr. Paul Tunnah, pharmaphorum CEO; and Sheela Upadhyaya, senior NHS manager. 

Lessons in Specialty Data Integration: Best Practices for Small and Emerging Biopharma Companies

27.03.2015

John Giannouris, Sr. Principal and Practice Leader, Specialty Pharmacy Data Integration Center of Excellence, IMS Health, discusses best practices for overcoming the challenges associated with managing fragmented specialty pharmaceutical data.

340B Duplicate Discounts: Managed Medicaid and Contract Pharmacies

06.03.2015

IMS Health’s Jeremy Docken, Director, Operations, Data Niche Division, shares information regarding challenges states have had with implementing procedures to protect manufacturers from 340B duplicate discounts.

Colorectal Cancer - Current and Future Market Dynamics

04.03.2015

IMS Health Disease Insights’ Mohamed Muhsin, Oncology Lead, and Farhana Begum, Oncology Analyst, discuss the colorectal cancer market, with the focus on patient dynamics and segmentation, and current clinical and commercial market dynamics and opportunities. They will also review the drug development pipeline and present a market forecast.

Market Developments in Diabetes-Current and Future Treatment Trends in Major Pharmerging Markets

29.01.2015

IMS Health’s Christine Henry Ph.D., senior analyst, Cardiovascular/Metabolic Areas, and Donny Wong Ph.D. director, Disease Insights and Therapy Analysis, discuss the key market drivers for drug developers active in the diabetes market and those looking to enter it.

The Third Sector: A Growing Opportunity in the Pharmaceutical Market?

12.12.2014

IMS Health's thought leaders Sarah Rickwood, Stephen Flostrand and Elena Klimova discuss the growing importance of a non-original but significant product sector that has grown to be ten times more valuable than the entirety of biosimilars and non-original biologics.

Using Lean Sigma to Improve Your Rebate Administration Process

18.11.2014

Lisa Cooney, vice president, Process Engineering, IMS Health, and Carly Sweeney Brown, team leader, Managed Markets Services, IMS Health, discuss how IMS Health and Manufacturers have used the Lean Sigma tools to improve the rebate
administration process.

A Review of the Neuropathic Pain Market

17.11.2014

IMS Health’s Peter Alfinito, Ph.D., lead analyst, Central Nervous System Disorders, gives an overview of the U.S. neuropathic pain market, including a detailed look at market sizing, current market dynamics, and the impact of new products over the next ten years.

See More